

Appendix 8. Discrimination of risk predicting models in complete-case analysis or using cirrhosis at initiation of AVT in calculation of on-treatment scores

Supplementary Table 8-1. Discrimination of risk predicting models in complete-case analysis

| MODEL | Year 2.5 | Year 3 | Year 3.5 | Year 4 | Year 4.5 | Year 5 |
|--|------------------|------------------|------------------|------------------|------------------|------------------|
| Untreated models without the cirrhosis variable | | | | | | |
| REACH-B | 0.58 (0.46,0.70) | 0.61 (0.46,0.76) | 0.56 (0.34,0.79) | 0.55 (0.42,0.68) | 0.56 (0.35,0.77) | 0.56 (0.30,0.82) |
| NGM1-HCC | 0.62 (0.48,0.75) | 0.65 (0.48,0.81) | 0.55 (0.33,0.77) | 0.55 (0.42,0.67) | 0.54 (0.37,0.71) | 0.54 (0.28,0.81) |
| NGM2-HCC | 0.57 (0.43,0.70) | 0.63 (0.47,0.79) | 0.52 (0.28,0.75) | 0.53 (0.42,0.65) | 0.55 (0.42,0.69) | 0.53 (0.27,0.79) |
| Untreated models with the cirrhosis variable | | | | | | |
| GAG-HCC | 0.69 (0.60,0.77) | 0.67 (0.57,0.76) | 0.72 (0.64,0.79) | 0.71 (0.64,0.78) | 0.67 (0.57,0.76) | 0.69 (0.53,0.85) |
| Treated or mixed models without the cirrhosis variable | | | | | | |
| mREACH-BI | 0.64 (0.52,0.76) | 0.69 (0.54,0.84) | 0.58 (0.37,0.79) | 0.64 (0.54,0.74) | 0.61 (0.36,0.86) | 0.58 (0.37,0.78) |
| mREACH-BII | 0.66 (0.54,0.79) | 0.68 (0.53,0.83) | 0.58 (0.38,0.78) | 0.67 (0.58,0.76) | 0.66 (0.46,0.87) | 0.58 (0.39,0.77) |
| LSM-HCC | 0.69 (0.58,0.81) | 0.64 (0.51,0.77) | 0.61 (0.49,0.73) | 0.68 (0.56,0.80) | 0.64 (0.51,0.77) | 0.61 (0.47,0.74) |
| SAGE-B | 0.74 (0.65,0.82) | 0.63 (0.51,0.76) | 0.64 (0.54,0.75) | 0.71 (0.61,0.81) | 0.56 (0.42,0.70) | 0.57 (0.43,0.70) |
| mPAGE-B | 0.68 (0.59,0.77) | 0.64 (0.54,0.74) | 0.64 (0.55,0.73) | 0.65 (0.56,0.75) | 0.63 (0.51,0.75) | 0.62 (0.47,0.77) |
| PAGE-B | 0.66 (0.57,0.75) | 0.63 (0.54,0.73) | 0.64 (0.55,0.73) | 0.64 (0.52,0.75) | 0.66 (0.53,0.79) | 0.65 (0.49,0.82) |
| aMAP | 0.69 (0.59,0.79) | 0.66 (0.55,0.77) | 0.64 (0.54,0.73) | 0.68 (0.58,0.78) | 0.65 (0.53,0.78) | 0.65 (0.49,0.82) |
| Treated or mixed models with the cirrhosis variable | | | | | | |
| AASL-HCC | 0.71 (0.61,0.80) | 0.68 (0.59,0.77) | 0.72 (0.64,0.79) | 0.71 (0.63,0.78) | 0.66 (0.56,0.77) | 0.67 (0.51,0.84) |
| CAMD | 0.69 (0.60,0.78) | 0.67 (0.58,0.77) | 0.71 (0.63,0.79) | 0.69 (0.61,0.77) | 0.65 (0.54,0.75) | 0.69 (0.53,0.84) |
| REAL-B | 0.71 (0.62,0.80) | 0.69 (0.59,0.78) | 0.71 (0.62,0.80) | 0.72 (0.63,0.81) | 0.70 (0.60,0.80) | 0.68 (0.51,0.85) |
| CU-HCC | 0.66 (0.56,0.77) | 0.64 (0.52,0.75) | 0.70 (0.62,0.78) | 0.71 (0.61,0.80) | 0.65 (0.54,0.76) | 0.72 (0.57,0.87) |
| RWS-HCC | 0.73 (0.64,0.82) | 0.72 (0.62,0.82) | 0.75 (0.66,0.83) | 0.78 (0.73,0.84) | 0.75 (0.64,0.86) | 0.65 (0.47,0.82) |
| CAGE-B | 0.75 (0.68,0.83) | 0.67 (0.55,0.78) | 0.69 (0.60,0.78) | 0.74 (0.67,0.82) | 0.60 (0.49,0.71) | 0.57 (0.47,0.68) |

Supplementary Table 8-2. Discrimination of risk predicting models using cirrhosis at initiation of antiviral treatment in calculation of on-treatment scores

| MODEL | Year 2.5 (n=660) | Year 3 (n=640) | Year 3.5 (n=622) | Year 4 (n=603) | Year 4.5 (n=589) | Year 5 (n=562) |
|----------|------------------|------------------|------------------|------------------|------------------|------------------|
| GAG-HCC | 0.68 (0.60,0.76) | 0.68 (0.59,0.76) | 0.70 (0.62,0.77) | 0.71 (0.63,0.78) | 0.64 (0.55,0.72) | 0.64 (0.51,0.76) |
| AASL-HCC | 0.70 (0.61,0.77) | 0.69 (0.59,0.78) | 0.69 (0.61,0.76) | 0.70 (0.62,0.77) | 0.63 (0.54,0.71) | 0.62 (0.49,0.73) |
| CAMD | 0.69 (0.61,0.76) | 0.69 (0.60,0.78) | 0.70 (0.61,0.78) | 0.71 (0.62,0.78) | 0.63 (0.54,0.71) | 0.58 (0.47,0.68) |
| REAL-B | 0.71 (0.63,0.78) | 0.69 (0.59,0.77) | 0.69 (0.60,0.77) | 0.73 (0.64,0.81) | 0.66 (0.57,0.74) | 0.67 (0.53,0.78) |
| CU-HCC | 0.66 (0.57,0.73) | 0.66 (0.56,0.75) | 0.66 (0.58,0.74) | 0.70 (0.61,0.78) | 0.63 (0.54,0.71) | 0.65 (0.52,0.76) |
| RWS-HCC | 0.71 (0.62,0.80) | 0.70 (0.60,0.79) | 0.71 (0.62,0.79) | 0.77 (0.68,0.84) | 0.74 (0.62,0.83) | 0.65 (0.49,0.78) |